Estrogens and breast cancer: Does timing really matter?

Journal of Clinical Epidemiology

Volumn 57, Issue 8, 2004, Pages 763-765

  Stürmer, Til ^a   Manson, JoAnn E ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTROGEN; GESTAGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RISK; CLINICAL FEATURE; HORMONE SUBSTITUTION; HUMAN; NONHUMAN; NOTE; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT;

BREAST NEOPLASMS; ESTROGENS; FEMALE; HUMANS; OBESITY; RISK FACTORS;

EID: 5644295428     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2003.12.018     Document Type: Note

References (26)

1. Wiseman R.A. Breast cancer: critical data analysis concludes that estrogens are not the cause, however lifestyle changes can alter risk rapidly. J Clin Epidemiol. 57:2004;766-772. (this issue)
2. Hankinson S.E., Willett W.C., Manson J.E., Colditz G.A., Hunter D.J., Spiegelman D., Barbieri R.L., Speizer F.E. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 90:1998;1292-1299
3. Key T.J., Appleby P.N., Reeves G.K., Roddam A., Dorgan J.F., Longcope C., Stanczyk F.Z., Stephenson H.E. Jr., Falk R.T., Miller R., Schatzkin A., Allen D.S., Fentiman I.S., Wang D.Y., Dowsett M., Thomas H.V., Hankinson S.E., Toniolo P., Akhmedkhanov A., Koenig K., Shore R.E., Zeleniuch-Jacquotte A., Berrino F., Muti P., Micheli A., Krogh V., Sieri S., Pala V., Venturelli E., Secreto G., Barrett-Connor E., Laughlin G.A., Kabuto M., Akiba S., Stevens R.G., Neriishi K., Land C.E., Cauley J.A., Kuller L.H., Cummings S.R., Helzlsouer K.J., Alberg A.J., Bush T.L., Comstock G.W., Gordon G.B., Miller S.R., Longcope C. Endogenous Hormones Breast Cancer Collaborative Group. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 95:2003;1218-1226
4. International Agency for Research on Cancer. Hormonal Contraception and Post-menopausal hormonal therapy. IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 72:1999;IARC, Lyon
5. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E., Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 280:1998;605-613
6. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., Jackson R.D., Beresford S.A., Howard B.V., Johnson K.C., Kotchen J.M., Ockene J., Writing group for the Women's Health Initiative investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 288:2002;321-333
7. Kavanaugh C.J., Desai K.V., Calvo A., Brown P.H., Couldrey C., Lubet R., Green J.E. Pre-clinical applications of transgenic mouse mammary cancer models. Transgenic Res. 11:2002;617-633
8. Rastogi P., Vogel V.G. Update on breast cancer prevention. Oncology (Huntingt). 17:2003;799-805. discussion 808-10, 813.
9. Schiff R., Chamness G.C., Brown P.H. Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs). Breast Cancer Res. 5:2003;228-231
10. Kauff N.D., Satagopan J.M., Robson M.E., Scheuer L., Hensley M., Hudis C.A., Ellis N.A., Boyd J., Borgen P.I., Barakat R.R., Norton L., Castiel M., Nafa K., Offit K. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 346:2002;1609-1615
11. Sainsbury R. Ovarian ablation in the adjuvant treatment of premenopausal and perimenopausal breast cancer. Br J Surg. 90:2003;517-526
12. International Agency for Research on Cancer. Preamble to the IARC Monographs [Internet]. Updated January 1999. Accessed December 5, 2003. Available from http://monographs.iarc.fr/monoeval/preamble. html
13. Brenner H., Gefeller O., Greenland S. Risk and rate advancement periods as measures of exposure impact on the occurrence of chronic diseases. Epidemiology. 4:1993;229-236
14. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation. 97:1998;1837-1847
15. Liese A.D., Hense H.W., Brenner H., Lowel H., Keil U. Assessing the impact of classical risk factors on myocardial infarction by rate advancement periods. Am J Epidemiol. 152:2000;884-888
16. Rosner B., Colditz G.A., Willett W.C. Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. Am J Epidemiol. 139:1994;819-835
17. Rowland A.S., Baird D.D., Long S., Wegienka G., Harlow S.D., Alavanja M., Sandler D.P. Influence of medical conditions and lifestyle factors on the menstrual cycle. Epidemiology. 13:2002;668-674
18. Johnson K.C., Pan S., Mao Y., Canadian Cancer Registries Epidemiology Research Group. Risk factors for male breast cancer in Canada, 1994-1998. Eur J Cancer Prev. 11:2002;253-263
19. Goodwin J.S., Goodwin J.M. The tomato effect: rejection of highly efficacious therapies. JAMA. 251:1984;2387-2390
20. Manson J.E., Hsia J., Johnson K.C., Rossouw J.E., Assaf A.R., Lasser N.L., Trevisan M., Black H.R., Heckbert S.R., Detrano R., Strickland O.L., Wong N.D., Crouse J.R., Stein E., Cushman M., Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 349:2003;523-534
21. Henrich J.B., Kornguth P.J., Viscoli C.M., Horwitz R.I. Postmenopausal estrogen use and invasive versus in situ breast cancer risk. J Clin Epidemiol. 51:1998;1277-1283
22. Cotterchio M., Kreiger N., Theis B., Sloan M., Bahl S. Hormonal factors and the risk of breast cancer according to estrogen- and progesterone-receptor subgroup. Cancer Epidemiol Biomarkers Prev. 12:2003;1053-1060
23. Grodstein F., Clarkson T.B., Manson J.E. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med. 348:2003;645-650
24. Ray W.A. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 158:2003;915-920
25. Stürmer T, Spiegelman D, Schneeweiss S, Avorn J, Glynn RJ, Correcting effect estimates for unmeasured confounding in cohort studies with validation data using propensity score calibration. Am J Epidemiol (in press).
26. Manson J.E., Martin K.A. Postmenopausal hormone-replacement therapy. [Clinical practice] N Engl J Med. 345:2001;34-40